![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEideYQTGL1DndoA-U1dtGssu-Y4y2I7VG24ULLrvxePRzNn-XgKGmYajgii-AA8WI1Er5hQ49zwWGgB_JvyWJzRal9gjb-nKKiKcgZY8shEEP0Zd8-_AIgD8A4r_2LNRdvlntSvG5TBBx2-/s320/ENTA2021100620211115-717146.png)
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
http://www.priceseries.com/trade/ENTA-Enanta-Pharmaceuticals-Inc-stock-gains-46-percent-a-Trade-Record-by-priceSeries-2021100620211115.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments